Emerging drugs for urothelial carcinoma

Expert Opinion on Emerging Drugs

Volumn 18, Issue 4, 2013, Pages 477-494

  Gartrell, Benjamin A ^a   Sonpavde, Guru ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Bladder cancer; Molecular targets; Targeted therapy; Urothelial carcinoma

Indexed keywords

BEVACIZUMAB; CABOZANTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOVITINIB; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; GEMCITABINE; IPILIMUMAB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; MITOMYCIN; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VINBLASTINE; VINFLUNINE;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; DRUG TARGETING; FEBRILE NEUTROPENIA; HUMAN; MUCOSA INFLAMMATION; REVIEW; SEPSIS; TRANSITIONAL CELL CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; CISPLATIN; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84888866929     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2013.853741     Document Type: Review

References (129)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
2. David KA, Mallin K, Milowsky MI, et al. Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000. Cancer 2009;115:1435-47
3. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-75
4. Quek ML, Stein JP, Clark PE, et al. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer 2003;98:955-61
5. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997;15:2564-9
6. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006;42:50-4
7. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602-8
8. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985;133:403-7
9. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066-73
10. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77
11. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012;30:1107-13
12. Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006;107:506-13
13. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30:191-9
14. Galsky MD, Chen GJ, Oh WK, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol 2012;23:406-10
15. McCaffrey JA, Hilton S, Mazumdar M, et al. phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997;15:1853-7
16. Vaughn DJ, Broome CM, Hussain M, et al. phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002;20:937-40
17. Papamichael D, Gallagher CJ, Oliver RT, et al. phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 1997;75:606-7
18. Bellmunt J, Theodore C, Demkov T, et al. phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27:4454-61
19. International Collaboration of T, Medical Research Council Advanced Bladder Cancer. Working P; European Organisation for R. et al.
20. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-66
21. Sonpavde G, Goldman BH, Speights VO, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 2009;115:4104-9
22. James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012;366:1477-88
23. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17:3173-81
24. Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010;28:1850-5
25. Sonpavde G, Pond GR, Fougeray R, et al. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase II trials. Eur Urol 2013;63:717-23
26. Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol 2011;185:72-8
27. Schrag D, Mitra N, Xu F, et al. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology 2005;65:1118-25
28. David KA, Milowsky MI, Ritchey J, et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol 2007;178:451-4
29. Sonpavde G, Watson D, Tourtellott M, et al. Frequency of cisplatin administration in patients presenting with advanced urothelial carcinoma in the community. J Clin Oncol 2012;30(Suppl 5):abstract 285
30. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006;24:5552-64
31. Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, et al. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol 2010;28:401-8
32. Fadl-Elmula I. Chromosomal changes in uroepithelial carcinomas. Cell Chromosome 2005;4:1
33. Fadl-Elmula I, Gorunova L, Mandahl N, et al. Karyotypic characterization of urinary bladder transitional cell carcinomas. Genes Chromosomes Cancer 2000;29:256-65
34. C1hekaluk Y, Wu CL, Rosenberg J, et al. Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value. PLoS One 2013;8:e60927
35. Fu YP, Kohaar I, Rothman N, et al. Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. Proc Natl Acad Sci USA 2012;109:4974-9
36. Dickinson AJ, Fox SB, Persad RA, et al. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994;74:762-6
37. Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995;87:1603-12
38. Miyake H, Hara I, Yamanaka K, et al. Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer. Urology 1999;53:302-7
39. Crew JP, O'Brien T, Bicknell R, et al. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol 1999;161:799-804
40. Bernardini S, Fauconnet S, Chabannes E, et al. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 2001;166:1275-9
41. Kopparapu PK, Boorjian SA, Robinson BD, et al. Expression of VEGF and Its receptors VEGFR1/VEGFR2 Is Associated with Invasiveness of Bladder Cancer. Anticancer Res 2013;33:2381-90
42. Nakanishi R, Oka N, Nakatsuji H, et al. Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer. Urol Int 2009;83:98-106
43. Hahn NM, Stadler WM, Zon RT, et al. phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: hoosier Oncology Group GU 04-75. J Clin Oncol 2011;29:1525-30
44. Balar AV, Apolo AB, Ostrovnaya I, et al. phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol 2013;31:724-30
45. Chaudhary UB, Golshayan AR, Brisendine A, et al. phase II trial of neoadjuvant cisplatin, gemcitabine, and bevacizumab followed by radical cystectomy (RC) in patients with muscle-invasive transitional cell carcinoma (TCC) of the bladder. J Clin Oncol 2011;29(Suppl 7):abstract 276
46. Siefker-Radtke AO, Kamat AM, Corn PG, et al. Neoadjuvant chemotherapy with trial at the M. D. Anderson Cancer Center. J Clin Oncol 2012;30(Suppl 5):abstract 261
47. Sonpavde G, Jian W, Liu H, et al. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 2009;27:391-9
48. Bellmunt J, Gonzalez-Larriba JL, Prior C, et al. phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol 2011;22:2646-53
49. Gallagher DJ, Milowsky MI, Gerst SR, et al. phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010;28:1373-9
50. Grivas P, Nanus DM, Stadler WM, et al. Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC). J Clin Oncol 2012;30(Suppl 5):abstract 265
51. Galsky MD, Hahn NM, Powles T, et al. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 2013;11:175-81
52. Balar AV, Iyer G, Apolo AB, et al. phase II trial of neoadjuvant gemcitabine (G) and cisplatin (C) with sunitinib in patients (pts) with muscle-invasive bladder cancer (MIBC). J Clin Oncol 2012;30(Suppl):abstract 4581
53. Sridhar SS, Winquist E, Eisen A, et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH phase II Consortium. Invest New Drugs 2011;29:1045-9
54. Dreicer R, Li H, Stein M, et al. phase II trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009;115:4090-5
55. Mehnert JM, Mortazavi A, Stein MN, et al. A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): preliminary safety and outcome. J Clin Oncol 2011;29(Suppl 7):abstract 278
56. Krege S, Rexer H, vom Dorp F, et al. Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05) [abstract 4574]. J Clin Oncol 2010;28(Suppl):15s
57. Necchi A, Mariani L, Zaffaroni N, et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase II trial. Lancet Oncol 2012;13:810-16
58. Pili R, Qin R, Flynn PJ, et al. MC0553: a phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. J Clin Oncol 2011;29(Suppl 7):abstract 259
59. Gerullis H, Eimer C, Ecke TH, et al. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy. Anticancer Drugs 2013;24:422-5
60. Choueiri TK, Ross RW, Jacobus S, et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol 2012;30:507-12
61. Twardowski P, Stadler WM, Frankel P, et al. phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology 2010;76:923-6
62. Lonn U, Lonn S, Friberg S, et al. Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1995;1:1189-94
63. Sriplakich S, Jahnson S, Karlsson MG. Epidermal growth factor receptor expression: predictive value for the outcome after cystectomy for bladder cancer? BJU Int 1999;83:498-503
64. Chaux A, Cohen JS, Schultz L, et al. High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues. Hum Pathol 2012;43:1590-5
65. Wong YN, Litwin S, Vaughn D, et al. phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol 2012;30:3545-51
66. Grivas P, Agarwal N, Siefker-Radtke AO, et al. Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC). J Clin Oncol 2012;30(Suppl):abstract 4506
67. Petrylak DP, Tangen CM, Van Veldhuizen PJ. Jr., et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int 2010;105:317-21
68. Philips GK, Halabi S, Sanford BL, et al. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol 2009;20:1074-9
69. Pruthi RS, Nielsen M, Heathcote S, et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int 2010;106:349-54
70. Pruthi R, Kim W, Kurpad R, et al. A phase II study of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: Preliminary clinical results [abstract 246]. Genitourinary Cancers Symposium; 2009
71. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007;25:2218-24
72. Oudard S, Culine S, Vieillefond A, et al. Multicenter randomized phase ii trial of gemcitabine-platinum with or without Trastuzumab (T) in Advanced/Metastatic Urothelial Carcinoma (A/MUC) with HER2 overexpression. ESMO 2012;2012:abstract 1111
73. Galsky MD, Von Hoff DD, Neubauer M, et al. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs 2012;30:695-701
74. Wulfing C, Machiels JP, Richel DJ, et al. A single-arm, multicenter, open-label phase II study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009;115:2881-90
75. Daugaard G, Sengeløv L, Agerbaek M, et al. phase I results from a study of lapatinib with gemcitabine and cisplatin (GC) in advanced/metastatic bladder cancer. J Clin Oncol 2013;31(Suppl 6):abstract 252
76. Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA 2007;104:3967-72
77. Carthon BC, Wolchok JD, Yuan J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010;16:2861-71
78. Malmstrom PU, Loskog AS, Lindqvist CA, et al. AdCD40L immunogene therapy for bladder carcinoma-the first phase I/IIa trial. Clin Cancer Res 2010;16:3279-87
79. Sharma P, Shen Y, Wen S, et al. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 2006;12:5442-7
80. Dyrskjot L, Zieger K, Kissow Lildal T, et al. Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma. Br J Cancer 2012;107:116-22
81. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
82. Sjodahl G, Lauss M, Gudjonsson S, et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS One 2011;6:e18583
83. Hornigold N, Devlin J, Davies AM, et al. Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 1999;18:2657-61
84. Milowsky MI, Iyer G, Regazzi AM, et al. phase II study of everolimus in metastatic urothelial cancer. BJU Int 2013;112:462-70
85. Seront E, Rottey S, Sautois B, et al. phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 2012;23:2663-70
86. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013;31:412-19
87. Apolo AB, Lee YH, Cecchi F, et al. Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC). J Clin Oncol 2013;31(Suppl 6):abstract 314
88. Wang P, Nishitani MA, Tanimoto S, et al. Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor. Urology 2007;69:780-4
89. Sanchez-Carbayo M, Socci ND, Lozano JJ, et al. Profiling bladder cancer using targeted antibody arrays. Am J Pathol 2006;168:93-103
90. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805-13
91. Yeh CY, Shin SM, Yeh HH, et al. Transcriptional activation of the Axl and PDGFR-alpha by c-Met through a rasand Src-independent mechanism in human bladder cancer. BMC Cancer 2011;11:139
92. Cheng HL, Trink B, Tzai TS, et al. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol 2002;20:1544-50
93. Miyata Y, Sagara Y, Kanda S, et al. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and-7 and E-cadherin. Hum Pathol 2009;40:496-504
94. Apolo AB, Parnes HL, Madan RA, et al. A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma. J Clin Oncol 2013;31(Suppl):abstract TPS4589
95. Rosenberg JE, Werner L, Bamias A, et al. FGFR3 protein expression and gene mutation in primary and metastatic urothelial carcinoma (UC) tumors. J Clin Oncol 2012;30(Suppl):abstract 4577
96. Milowsky MI, Dittrich C, Martinez ID, et al. Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3. J Clin Oncol 2013;31(Suppl 6):abstract 255
97. Ischia J, So AI. The role of heat shock proteins in bladder cancer. Nat Rev Urol 2013;10:386-95
98. Kamada M, So A, Muramaki M, et al. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther 2007;6:299-308
99. Levitt JM, Yamashita H, Jian W, et al. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. Mol Cancer Ther 2010;9:1128-35
100. Hahn NM, Daneshmand S, Posadas EM, et al. A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): hoosier Oncology Group GU07-122 trial. J Clin Oncol 2012;30(Suppl):abstract 4586
101. Zhang Z, Zhang G, Kong C. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Urol Oncol 2011
102. Stadler WM, Vaughn DJ, Sonpavde G, et al. Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC). J Clin Oncol 2011;29(Suppl): abstract 4567
103. Winquist E, Moore MJ, Chi KN, et al. A multinomial phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol 2005;23:143-9
104. Theodore C, Geoffrois L, Vermorken JB, et al. Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur J Cancer 2005;41:1150-7
105. Shen SS, Smith CL, Hsieh JT, et al. Expression of estrogen receptors-alpha and-beta in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006;106:2610-16
106. Lerner SP, Sternberg CN, Younes M, et al. phase II trial of tamoxifen for progressive advanced urothelial carcinoma following prior chemotherapy. J Clin Oncol 2012;30(Suppl):abstract e15003
107. Engel J, Emons G, Pinski J, Schally AV. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. Expert Opin Investig Drugs 2012;21:891-9
108. Gomez-Abuin G, Winquist E, Stadler WM, et al. A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia. Invest New Drugs 2007;25:181-5
109. Rosenberg JE, Halabi S, Sanford BL, et al. phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Ann Oncol 2008;19:946-50
110. Schneider BJ, Kalemkerian GP, Bradley D, et al. phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Invest New Drugs 2012;30:249-57
111. Cheung EM, Quinn DI, Tsao-Wei DD, et al. phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy-California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial. J Clin Oncol (Meeting Abstracts) 2008;26(15-Suppl):16058
112. Smith JA, Wilson L, Azarenko O, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 2010;49:1331-7
113. Quinn DI, Aparicio A, Tsao-Wei DD, et al. phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)-Final report: a California Cancer Consortium-led NCI/CTEPsponsored trial (abstract 4539). J Clin Oncol 2010;28(Suppl):15s
114. Quinn DI, Twardowski PW, Wei YE, et al. phase II study of eribulin in platinum-treated, tubulin naive advanced urothelial cancer (UC)-A California Cancer Consortium trial (NCI/CTEP 7435) [abstract 2704]. European Cancer Congress; 2013
115. De Santis M, Wiechno P, Lucas C, et al. Preliminary data on feasibility of vinflunine (VFL)-based combinations as 1st line in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL/gemcitabine vs. VFL/CBDCA in a randomised international phase II trial (JASINT1) [abstract 2703]. European Cancer Congress; 2013
116. Grivas PD, Hussain M, Hafez K, et al. A phase II Trial of Neoadjuvant nab-paclitaxel, Carboplatin, and Gemcitabine (ACaG) in Patients With Locally Advanced Carcinoma of the Bladder. Urology 2013;82:111-17
117. Ko YJ, Canil CM, Mukherjee SD, et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase II study. Lancet Oncol 2013;14:769-76
118. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79
119. Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007;18:522-8
120. Nikitas N, Karadimou A, Tsitoura E, et al. Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study. Pharmacogenomics 2012;13:1595-607
121. Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol 2011;22:139-44
122. Gallagher DJ, Vijai J, Hamilton RJ, et al. Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host. Ann Oncol 2013
123. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005;11:2625-36
124. Dancik G, Aisner D, Theodorescu D. A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors. PLoS Curr 2011;3:RRN1248
125. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA 2007;104:13086-91
126. Williams PD, Cheon S, Havaleshko DM, et al. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res 2009;69:8302-9
127. Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol 2011;29:2432-8
128. Sonpavde G, Galsky MD, Vogelzang NJ. First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and-ineligible patients? J Clin Oncol 2010;28:e441-2.author reply e443-4
129. Cheung EM, Quinn DI, Tsao-Wei DD, et al. phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy-California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial. J Clin Oncol (Meeting Abstracts) 2008;26(15-Suppl):16058